Patents by Inventor Francisco J. Schopfer
Francisco J. Schopfer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230321022Abstract: Various embodiments of this invention are directed to pharmaceutical compositions and methods for treating disease. The compositions of such embodiments include thiolated nitro fatty acids. The methods of various embodiments include administering an effective amount of any of these pharmaceutical compositions to a patient in need of treatment.Type: ApplicationFiled: May 22, 2023Publication date: October 12, 2023Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Bruce A. Freeman, Francisco J. Schopfer, Steven Woodcock, Nicholas Khoo
-
Patent number: 11723897Abstract: Compounds of formula I and their metabolites are potent mediators of an inflammatory response: where a, b, c, d, e, f, V, W, X, Y, Ra, Ra?, Rb, Rb?, Rc, and Rc? are defined herein. In particular, the compounds of the invention are candidate therapeutics for treating inflammatory conditions.Type: GrantFiled: October 14, 2020Date of Patent: August 15, 2023Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Bruce A. Freeman, Francisco J. Schopfer
-
Publication number: 20230241019Abstract: A method comprising administering to a subject having an aneurysm, suspected of having an aneurysm, or at risk of developing an aneurysm, a therapeutically effective amount of a compound selected from (i) a nitroalkene fatty acid, (ii) an unsaturated fatty acid having an electron withdrawing group, a leaving group, and a carbon-carbon double bond disposed between the electron withdrawing group and the leaving group, (iii) a thiolated nitro fatty acid, (iv) a dicarboxylic acid compound containing an electron withdrawing group, or a mixture of at least two of (i)-(iv).Type: ApplicationFiled: April 20, 2021Publication date: August 3, 2023Applicants: University of Pittsburgh - Of the Commonwealth System of Higher Education, The Regents of the University of MichiganInventors: Francisco J. Schopfer, Bruce A. Freeman, Yang Zhao, Yuqing E. Chen, Jifeng Zhang
-
Patent number: 11642325Abstract: Various embodiments of this invention are directed to pharmaceutical compositions and methods for treating disease. The compositions of such embodiments include dicarboxylic acid compounds containing electron withdrawing groups, alkyl esters of dicarboxylic acids containing electron withdrawing groups, or compounds of Formulae I to X. The methods of various embodiments include administering an effective amount of any of these pharmaceutical compositions to a patient in need of treatment.Type: GrantFiled: July 27, 2020Date of Patent: May 9, 2023Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Bruce A. Freeman, Francisco J. Schopfer
-
Publication number: 20230108270Abstract: A composition comprising a complex of a cyclodextrin with a nitroalkene.Type: ApplicationFiled: March 15, 2021Publication date: April 6, 2023Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Bruce A. Freeman, Francisco J. Schopfer, Sonia R. Salvatore
-
Patent number: 11491128Abstract: Various embodiments of this invention are directed to pharmaceutical compositions and methods for treating disease. The compositions of such embodiments include reversible nitroxide derivatives of nitroalkenes. The methods of various embodiments include administering an effective amount of any of these pharmaceutical compositions to a patient in need of treatment.Type: GrantFiled: August 17, 2020Date of Patent: November 8, 2022Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Marco Fazzari, Bruce A. Freeman, Francisco J. Schopfer
-
Publication number: 20220273703Abstract: Disclosed is a method for treating or preventing nephrogenic diabetes insipidus (NDI) in a subject that includes administering to the subject a therapeutically effective amount of a Nuclear factor-erythroid 2-related factor 2 (Nrf2) inducer, thereby treating or preventing the NDI in the subject. The Nrf2 inducer may be a fumarate, a nitro fatty acid, a bardoxolone or sulforaphane. Also disclosed is a pharmaceutical composition comprising (i) a Nuclear factor-crythroid 2-related factor 2 (Nrf2) inducer and (ii) lithium or a lithium salt.Type: ApplicationFiled: July 22, 2020Publication date: September 1, 2022Applicant: University Of Pittsburgh-Of The Commonwealth System Of Higher EducationInventors: Francisco J. Schopfer, Dario A. Vitturi Iglesias, Soma Jobbagy
-
Publication number: 20220040134Abstract: A method comprising co-administering to a subject having cancer, suspected of having cancer, or at risk of developing cancer: a therapeutically effective amount of at least one compound (a) selected from (a)(i) a nitroalkene fatty acid, (a)(ii) an unsaturated fatty acid having an electron withdrawing group, a leaving group, and a carbon-carbon double bond disposed between the electron withdrawing group and the leaving group, (a)(iii) a thiolated nitro fatty acid, or (a)(iv) a dicarboxylic acid compound containing an electron withdrawing group; and a therapeutically effective amount of at least one anti-neoplastic agent (b), wherein the cancer is a cancer with hereditary etiology of defects in DNA repair genes, a cancer with a high rate of spontaneous genomic instability, a cancer that responds well to DNA damaging agent(s), or a cancer that responds well to a combination of DNA damaging agent(s) with immunotherapy.Type: ApplicationFiled: November 14, 2019Publication date: February 10, 2022Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Bruce A. Freeman, Carola Neumann, Francisco J. Schopfer
-
Publication number: 20210236469Abstract: Compounds of formula I and their metabolites are potent mediators of an inflammatory response: where a, b, c, d, e, f, V, W, X, Y, Ra, Ra?, Rb, Rb?, Rc, and Rc? are defined herein. In particular, the compounds of the invention are candidate therapeutics for treating inflammatory conditions.Type: ApplicationFiled: October 14, 2020Publication date: August 5, 2021Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Bruce A. Freeman, Francisco J. Schopfer
-
Publication number: 20210220315Abstract: Nitro oleic acid and related metabolites are agonists of PPAR-?. Surprisingly, nitro oleic acid is a more potent agonist of PPAR-?, relative to nitro linoleic acid. Thus, nitro oleic acid and its metabolites, as well as their pharmaceutically acceptable salts and prodrug forms, are candidate therapeutics for the treatment of type-2 diabetes, which results from insulin resistance accompanying the improper functioning of PPAR-?.Type: ApplicationFiled: November 17, 2020Publication date: July 22, 2021Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Bruce A. Freeman, Francisco J. Schopfer
-
Patent number: 10869850Abstract: Nitro oleic acid and related metabolites are agonists of PPAR-?. Surprisingly, nitro oleic acid is a more potent agonist of PPAR-?, relative to nitro linoleic acid. Thus, nitro oleic acid and its metabolites, as well as their pharmaceutically acceptable salts and prodrug forms, are candidate therapeutics for the treatment of type-2 diabetes, which results from insulin resistance accompanying the improper functioning of PPAR-?.Type: GrantFiled: January 21, 2020Date of Patent: December 22, 2020Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Bruce A. Freeman, Francisco J. Schopfer
-
Publication number: 20200375936Abstract: Various embodiments of this invention are directed to pharmaceutical compositions and methods for treating disease. The compositions of such embodiments include reversible nitroxide derivatives of nitroalkenes. The methods of various embodiments include administering an effective amount of any of these pharmaceutical compositions to a patient in need of treatment.Type: ApplicationFiled: August 17, 2020Publication date: December 3, 2020Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Marco Fazzari, Bruce A. Freeman, Francisco J. Schopfer
-
Publication number: 20200360323Abstract: Various embodiments of this invention are directed to pharmaceutical compositions and methods for treating disease. The compositions of such embodiments include dicarboxylic acid compounds containing electron withdrawing groups, alkyl esters of dicarboxylic acids containing electron withdrawing groups, or compounds of Formulae I to X. The methods of various embodiments include administering an effective amount of any of these pharmaceutical compositions to a patient in need of treatment.Type: ApplicationFiled: July 27, 2020Publication date: November 19, 2020Applicant: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONInventors: Bruce A. Freeman, Francisco J. Schopfer
-
Patent number: 10835518Abstract: Compounds of formula I and their metabolites are potent mediators of an inflammatory response: where a, b, c, d, e, f, V, W, X, Y, Ra, Rb, Rb?, Rc, and Rc? are defined herein. In particular, the compounds of the invention are candidate therapeutics for treating inflammatory conditions.Type: GrantFiled: January 3, 2019Date of Patent: November 17, 2020Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Bruce A. Freeman, Francisco J. Schopfer
-
Publication number: 20200352890Abstract: Various embodiments of this invention are directed to pharmaceutical compositions and methods for treating disease. The compositions of such embodiments include thiolated nitro fatty acids. The methods of various embodiments include administering an effective amount of any of these pharmaceutical compositions to a patient in need of treatment.Type: ApplicationFiled: July 23, 2020Publication date: November 12, 2020Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Bruce A. Freeman, Nicholas Khoo, Francisco J. Schopfer, Steven Woodcock
-
Patent number: 10751310Abstract: Various embodiments of this invention are directed to pharmaceutical compositions and methods for treating disease. The compositions of such embodiments include dicarboxylic acid compounds containing electron withdrawing groups, alkyl esters of dicarboxylic acids containing electron withdrawing groups, or compounds of Formulae I to X. The methods of various embodiments include administering an effective amount of any of these pharmaceutical compositions to a patient in need of treatment.Type: GrantFiled: March 2, 2017Date of Patent: August 25, 2020Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Bruce A. Freeman, Francisco J. Schopfer
-
Publication number: 20200230095Abstract: Nitro oleic acid and related metabolites are agonists of PPAR-?. Surprisingly, nitro oleic acid is a more potent agonist of PPAR-?, relative to nitro linoleic acid. Thus, nitro oleic acid and its metabolites, as well as their pharmaceutically acceptable salts and prodrug forms, are candidate therapeutics for the treatment of type-2 diabetes, which results from insulin resistance accompanying the improper functioning of PPAR-?.Type: ApplicationFiled: January 21, 2020Publication date: July 23, 2020Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Bruce A. Freeman, Francisco J. Schopfer
-
Patent number: 10576051Abstract: Nitro oleic acid and related metabolites are agonists of PPAR-?. Surprisingly, nitro oleic acid is a more potent agonist of PPAR-?, relative to nitro linoleic acid. Thus, nitro oleic acid and its metabolites, as well as their pharmaceutically acceptable salts and prodrug forms, are candidate therapeutics for the treatment of type-2 diabetes, which results from insulin resistance accompanying the improper functioning of PPAR-?.Type: GrantFiled: February 20, 2019Date of Patent: March 3, 2020Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Bruce A. Freeman, Francisco J. Schopfer
-
Publication number: 20190274987Abstract: Nitro oleic acid and related metabolites are agonists of PPAR-?. Surprisingly, nitro oleic acid is a more potent agonist of PPAR-?, relative to nitro linoleic acid. Thus, nitro oleic acid and its metabolites, as well as their pharmaceutically acceptable salts and prodrug forms, are candidate therapeutics for the treatment of type-2 diabetes, which results from insulin resistance accompanying the improper functioning of PPAR-?.Type: ApplicationFiled: February 20, 2019Publication date: September 12, 2019Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Bruce A. Freeman, Francisco J. Schopfer
-
Publication number: 20190275009Abstract: Compounds of formula I and their metabolites are potent mediators of an inflammatory response: where a, b, c, d, e, f, V, W, X, Y, Ra, Rb, Rb?, Rc, and Rc? are defined herein. In particular, the compounds of the invention are candidate therapeutics for treating inflammatory conditions.Type: ApplicationFiled: January 3, 2019Publication date: September 12, 2019Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Bruce A. Freeman, Francisco J. Schopfer